Baidu
map

Cancer Cell:科学家或可成功预测白血病的发生

2016-01-15 佚名 生物谷

最近,发表于国际杂志Cancer Cell上的一项研究论文中,来自麦克马斯特大学等处的研究人员通过研究成功鉴别出了致死性癌症的早期发病阶段,同时也成功预测了这种疾病在机体中的发病机制。 研究人员Mick Bhatia教授指出,我们发现了从健康到癌性的血液干细胞的过渡常常发生在有区别的过程中,这项研究中我们鉴别出了两个关键的步骤。文章中研究人员对骨髓增生异常综合征(MDS)成功地进行了指纹图谱分析

最近,发表于国际杂志Cancer Cell上的一项研究论文中,来自麦克马斯特大学等处的研究人员通过研究成功鉴别出了致死性癌症的早期发病阶段,同时也成功预测了这种疾病在机体中的发病机制。

研究人员Mick Bhatia教授指出,我们发现了从健康到癌性的血液干细胞的过渡常常发生在有区别的过程中,这项研究中我们鉴别出了两个关键的步骤。文章中研究人员对骨髓增生异常综合征(MDS)成功地进行了指纹图谱分析,骨髓增生异常综合征是血细胞转化为急性髓性白血病(AML)的一个阶段,急性髓性白血病在白血病患者中大约占到了30%左右。本文研究为后期进行急性髓性白血病的准确和早期预测提供了一定可能。

急性髓性白血病是一种常见的成年人的白血病,每年大约有1300名加拿大人被预测会患上这种白血病;文章中研究者发现,当剔除名为GSK-3基因的一个链时(one version),另一部分就会被激活,但并不具有癌变性质,然而当该基因的第二部分(第二条链)也被剔除后就会导致急性髓性白血病的发生。

为了检测这一结果,研究人员同博洛尼亚大学的研究人员通过联合研究将初期的研究成果应用于对人类血液样本进行研究,这些血样收集自MDS患者,其中有些患者最终患上了急性髓性白血病;文章中研究人员进行了一项追溯研究,结果表明,对患者血样的基因表达分析可以帮助准确预测哪些患者会患上急性髓性白血病,而哪些患者不会患病。

最后研究人员说道,本文研究或可帮助他们鉴别哪些MDS患者会患上急性髓性白血病,然而下一步研究人员将进行更深入的研究来预测多种血液癌症,通过利用预测性基因的表达作为药物靶点来帮助抑制疾病的发生,当然这对于开发新型治疗多种白血病的药物也提供了很好的线索和依据。

原始出处:

Borhane Guezguez, Mohammed Almakadi,et al.GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia.Cancer Cell.Jan 11,2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780667, encodeId=343b1e8066781, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 00:41:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959539, encodeId=70b9195953970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 23 09:41:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869283, encodeId=55fe1869283be, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 26 20:41:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58113, encodeId=e55f58113a3, content=人类的进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58114, encodeId=bbf25811429, content=血液病太折磨病人, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57656, encodeId=4db85e65674, content=一大进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuHfSLw3PzIKiaSnTBUuAtRkrrxWpibukl35iciaGtBq4LYQv4ian1tPC3IdmzWI2dZ3cDC8wUg5CnBxlJ/0, createdBy=33a51675735, createdName=jiangxianchen, createdTime=Fri Jan 15 12:59:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780667, encodeId=343b1e8066781, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 00:41:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959539, encodeId=70b9195953970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 23 09:41:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869283, encodeId=55fe1869283be, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 26 20:41:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58113, encodeId=e55f58113a3, content=人类的进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58114, encodeId=bbf25811429, content=血液病太折磨病人, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57656, encodeId=4db85e65674, content=一大进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuHfSLw3PzIKiaSnTBUuAtRkrrxWpibukl35iciaGtBq4LYQv4ian1tPC3IdmzWI2dZ3cDC8wUg5CnBxlJ/0, createdBy=33a51675735, createdName=jiangxianchen, createdTime=Fri Jan 15 12:59:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
    2016-07-23 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780667, encodeId=343b1e8066781, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 00:41:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959539, encodeId=70b9195953970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 23 09:41:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869283, encodeId=55fe1869283be, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 26 20:41:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58113, encodeId=e55f58113a3, content=人类的进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58114, encodeId=bbf25811429, content=血液病太折磨病人, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57656, encodeId=4db85e65674, content=一大进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuHfSLw3PzIKiaSnTBUuAtRkrrxWpibukl35iciaGtBq4LYQv4ian1tPC3IdmzWI2dZ3cDC8wUg5CnBxlJ/0, createdBy=33a51675735, createdName=jiangxianchen, createdTime=Fri Jan 15 12:59:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1780667, encodeId=343b1e8066781, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 00:41:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959539, encodeId=70b9195953970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 23 09:41:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869283, encodeId=55fe1869283be, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 26 20:41:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58113, encodeId=e55f58113a3, content=人类的进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58114, encodeId=bbf25811429, content=血液病太折磨病人, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57656, encodeId=4db85e65674, content=一大进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuHfSLw3PzIKiaSnTBUuAtRkrrxWpibukl35iciaGtBq4LYQv4ian1tPC3IdmzWI2dZ3cDC8wUg5CnBxlJ/0, createdBy=33a51675735, createdName=jiangxianchen, createdTime=Fri Jan 15 12:59:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
    2016-01-17 lu2996

    人类的进步

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1780667, encodeId=343b1e8066781, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 00:41:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959539, encodeId=70b9195953970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 23 09:41:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869283, encodeId=55fe1869283be, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 26 20:41:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58113, encodeId=e55f58113a3, content=人类的进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58114, encodeId=bbf25811429, content=血液病太折磨病人, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57656, encodeId=4db85e65674, content=一大进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuHfSLw3PzIKiaSnTBUuAtRkrrxWpibukl35iciaGtBq4LYQv4ian1tPC3IdmzWI2dZ3cDC8wUg5CnBxlJ/0, createdBy=33a51675735, createdName=jiangxianchen, createdTime=Fri Jan 15 12:59:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
    2016-01-17 lu2996

    血液病太折磨病人

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1780667, encodeId=343b1e8066781, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Oct 22 00:41:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959539, encodeId=70b9195953970, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jul 23 09:41:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869283, encodeId=55fe1869283be, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Mar 26 20:41:00 CST 2016, time=2016-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58113, encodeId=e55f58113a3, content=人类的进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58114, encodeId=bbf25811429, content=血液病太折磨病人, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Sun Jan 17 11:25:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57656, encodeId=4db85e65674, content=一大进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuHfSLw3PzIKiaSnTBUuAtRkrrxWpibukl35iciaGtBq4LYQv4ian1tPC3IdmzWI2dZ3cDC8wUg5CnBxlJ/0, createdBy=33a51675735, createdName=jiangxianchen, createdTime=Fri Jan 15 12:59:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
    2016-01-15 jiangxianchen

    一大进步

    0

相关资讯

Blood:新药重建肿瘤抑制因子Ikaros基因功能治疗白血病

                                                    来自宾夕法尼亚州立大学医学院

陈竺和张亭栋获唐氏中医药发展奖

在12月22日举行的中国中医科学院成立60周年纪念大会上,由于在砷制剂治疗白血病研究中的杰出贡献,十二届全国人大常委会副委员长、中科院院士陈竺和哈尔滨医科大学教授张亭栋获颁第六届唐氏中医药发展奖中的中药研究奖。据介绍,陈竺和中国工程院院士陈赛娟等与张亭栋开展合作,研究砷剂治疗白血病的作用原理和临床效果。多年来,他们通过持续深入的多中心、前瞻性、规范的大组临床研究,发现维甲酸和砷剂合用的方案可使90

基因编辑的浪潮席卷临床

Layla Richards的白血病病症在细胞经DNA剪切酶作用后得到缓解。 公司准备检测基因编辑技术在人类疾病治疗的应用范围。 得益于基因编辑技术,Layla Richards能够接受来自另一个人的经过修饰的免疫细胞,这个一岁大的白血病患儿的病症得到了缓解。 她的病例是应用基因编辑技术成功治疗人类疾病的第二例,第一例是在去年应用于HIV感染者。公司计划进行类似的试验,并打算试验直接

PNAS:砷剂治疗白血病主要与抑制糖酵解的代谢途径有关

来自上海交通大学、中科院等处的研究人员,通过系统鉴别砷结合蛋白揭示出砷剂抑制了己糖激酶2(hexokinase-2,HK2)。这项研究发布在11月23日的《美国国家科学院院刊》(PNAS)上。

上海交通大学系统生物医学协同创新中心的陈竺(Zhu Chen)院士及陶生策(Sheng-ce Tao)教授是这篇论文的共同通讯作者。陈竺院士的主要研究方向是白血病靶向治疗相关的分子调控网络,研究基于分子机制的疾病预防、诊断和治疗的新途径,从根本上探索白血病靶向干预策略。陶生策教授的主要研究方向为蛋白质芯片的构建和应用研究、系统生物序高通量技术研发以及蛋白质翻译后修饰(糖基化,乙酰化)

急性早幼粒细胞白血病(Acute promyelocyte leukemia,APL)是一种有着特异基因与染色体核型改变的特殊类型急性白血病。APL 易见于中青年人,平均发病年龄为

Sci Transl Med:重大发现!新研究发现或可有效预防移植物抗宿主病的发生

Sci Transl Med:重大发现!新研究发现或可有效预防移植物抗宿主病的发生来自西雅图儿研所实验室的研究人员发现,使用现有药物可靶向移植物抗宿主病(GVHD)发生的遗传途径,GVHD是骨髓移植常见的也是致命的并发症,该研究成果在线发表于Science Translational Medicine。发生GVHD的患者,骨髓移植来源的T细胞可攻击移植受体。在美国每年有1万多名患者接受骨髓移植来治

Baidu
map
Baidu
map
Baidu
map